ResMed Shares Popped: What You Need to Know (RMD)

ResMed Shares Popped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ResMed (NYSE: RMD ) , a provider of medical products that treat respiratory disorders and sleep-disordered breathing, are no snooze today, shooting up 13% at one point following better-than-expected second-quarter earnings results.

So what: It was actually a fairly mixed quarter for ResMed, but shareholders seem pleased given that the company was able to surpass Wall Street's expectation of a $0.38 profit and deliver $0.42 in earnings to shareholders. On the other hand, sales actually fell short of consensus figures of $339.6 million, coming in at $332.7 million. Gross margin also contracted by 110 basis points during the quarter to 59.7%.

Now what: That last bit of info is what has me disturbed. Expenses rose by 11.7% during the quarter and the company is actually forecasting margins will range from 58% to 60% in 2012 -- so if anything, they have a better chance of shrinking from this most recent quarter. At 17 times forward earnings, ResMed appears fairly valued and unless it can significantly reduce expenses or grow its margin, I see plenty of other more enticing opportunities in the medical products sector.

Craving more input? Start by adding ResMed to your free and personalized watchlist so you can keep track of the latest news with the company.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.